Droperidol: cardiovascular toxicity and deaths

Wooltorton, Eric
April 2002
CMAJ: Canadian Medical Association Journal;4/2/2002, Vol. 166 Issue 7, p932
Academic Journal
Reports that Health Canada has warned that the injectable form of droperidol has been associated with deaths in Canada. Use of the drug as a neuroleptic and antiemetic; Approval for use for postoperative nausea and nausea associated with Meniere's disease; Way that patients should be screened for a history of or risk factors for long QT syndrome.


Related Articles

  • Dolasetron mesylate and serious cardiovascular reactions.  // WHO Drug Information;2006, Vol. 20 Issue 3, p185 

    The article reports that the manufacturer of dolasetron mesylate has issued warnings about QTc extension and the information on serious cardiovascular adverse reactions since the drug was approved in 1997. Health Canada knew about the off-label consumption of this drug in the pediatric...

  • betahistine hydrochloride.  // Royal Society of Medicine: Medicines;2002, p111 

    The article presents information on betahistine hydrochloride. This drug is an antinauseant which is used to treat the vertigo, hearing loss and tinnitus associated with Ménière's disease. It is administered orally. Its potential side effects include gastrointestinal disturbances,...

  • Health Canada issues reminder of benzocaine risks.  // Reactions Weekly;5/7/2011, Issue 1350, p3 

    This article reports on the move of Health Canada to remind the people of the risks associated with the use of topical benzocaine.

  • Report adverse reactions to Health Canada.  // British Columbia Medical Journal;Jun2013, Vol. 55 Issue 5, p233 

    The article announces that Health Canada is asking people to report a serious or unexpected adverse reaction because of any health product.

  • Growing support for the Canada Vigilance Program.  // Reactions Weekly;5/1/2010, Issue 1299, p3 

    The article deals with the 35% increase in the number of domestic reports of suspected adverse drug reactions submitted to Health Canada from 2008 to 2009.

  • Health Canada is advising consumers not to use Neophase Formula for Men.  // Reactions Weekly;8/12/2006, Issue 1114, p2 

    The article reports on the advise by Health Canada for consumers not to use Neophase Formula for Men from Vigor Nutriceutical Healthcare Inc., because it contained a modified version of sildenafil which can lead to serious health risks.

  • Health Canada update 2010.  // Reactions Weekly;7/23/2011, Issue 1361, p4 

    The article reports that 32,921 domestic adverse reaction cases were disclosed to Health Canada in 2010, with most of the cases involving reactions with pharmaceuticals and biotechnology products.

  • Febuxostat associated with DRESS syndrome?  // Reactions Weekly;Jun2015, Vol. 1555 Issue 1, p2 

    The article reports that Health Canada's safety review on the drug febuxostat (Uloric) and its association with agranulocytosis or DRESS syndrome.

  • Info on paediatric drug safety released by Health Canada.  // Reactions Weekly;1/28/2012, Issue 1386, p3 

    The article deals with the reports received by Health Canada regarding cardiometabolic adverse events suspected of being related to the use of second-generation antipsychotics in children and adolescents aged 18 years and below.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics